Pancreatic head vs pancreatic body/tail cancer: Are they different?

Figure 1 Survival and tumor location. A: Kaplan-Meier curve of overall survival in pancreatic head cancer and pancreatic body/tail cancer in the total population; B: Kaplan-Meier curve of overall survival in patients who underwent surgical resection versus those who did not.

Figure 2 Comparison of mutations between pancreatic head and pancreatic body/tail cancer.

Figure 3 Response to chemotherapy and tumor location. A: Kaplan Meier curve of recurrence free interval in patients with pancreatic head cancer who had resection and received FOLFIRINOX-based therapy versus gemcitabine based therapy (P = 0.5463); B: Kaplan Meier curve of recurrence free interval in patients with pancreatic body/tail cancer who had resection and received FOLFIRINOX-based therapy versus gemcitabine-based therapy (P = 0.6540); C: Kaplan Meier curve of response duration in patients with metastatic pancreatic head cancer who received FOLFIRINOX-based therapy versus gemcitabine-based therapy (P = 0.9146); D: Kaplan Meier curve of response duration in patients with metastatic pancreatic body/tail cancer who received FOLFIRINOX-based therapy versus gemcitabine-based therapy (P = 0.5244).